In contrast, the systemic ChREBP-KO led to the fewest preneoplastic foci after 36 weeks, while the tumor incidence was only slightly reduced compared to wildtype mice, and the hepatocyte proliferation remained unchanged. The gene discussed is MLXIPL; the disease is neoplasm.